Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease Gord Blackhouse, Nazila Assasi, Feng Xie, John Marshall, E. Jan Irvine, Kathryn Gaebel, Kaitryn Campbell, Rob Hopkins, Daria O’Reilly, Jean-Eric Tarride, Ron Goeree Journal of Crohn's and Colitis Volume 6, Issue 1, Pages 77-85 (February 2012) DOI: 10.1016/j.crohns.2011.07.007 Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions
Figure 1 Graphical representation of the Crohn's disease model structure and movement between health states after 1st line treatment. Journal of Crohn's and Colitis 2012 6, 77-85DOI: (10.1016/j.crohns.2011.07.007) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions
Figure 2 Graphical representation of the Crohn's Disease model structure and movement between health states after 2nd line treatment. Journal of Crohn's and Colitis 2012 6, 77-85DOI: (10.1016/j.crohns.2011.07.007) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions
Figure 3 Cost-effectiveness efficiency frontier for CD model. Journal of Crohn's and Colitis 2012 6, 77-85DOI: (10.1016/j.crohns.2011.07.007) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions
Figure 4 Cost-effectiveness acceptability curves. Journal of Crohn's and Colitis 2012 6, 77-85DOI: (10.1016/j.crohns.2011.07.007) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions